Online citations, reference lists, and bibliographies.
← Back to Search

Targeting The Central Nervous System: In Vivo Experiments With Peptide-derivatized Nanoparticles Loaded With Loperamide And Rhodamine-123.

G. Tosi, L. Costantino, F. Rivasi, B. Ruozi, E. Leo, A. V. Vergoni, R. Tacchi, A. Bertolini, M. A. Vandelli, F. Forni
Published 2007 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Polymeric nanoparticles (Np) represent one of the most innovative non-invasive approaches for the drug delivery to the central nervous system (CNS). It is known that the ability of the Np to cross the Blood Brain Barrier (BBB), thus allowing the drugs to exert their pharmacological activity in the central nervous district, is linked to their surface characteristics. Recently it was shown that the biocompatible polyester poly(d,l-lactide-co-glycolide) (PLGA) derivatized with the peptide H(2)N-Gly-l-Phe-d-Thr-Gly-l-Phe-l-Leu-l-Ser(O-beta-d-Glucose)-CONH(2) [g7] was a useful starting material for the preparation of Np (g7-Np); moreover, fluorescent studies showed that these Np were able to cross the BBB. In this research, g-7 Np were loaded with Loperamide in order to assess their ability as drug carriers for CNS, and with Rhodamine-123, in order to qualitatively determine their biodistribution in different brain macro-areas. A pharmacological evidence is given that g7-Np are able to cross the BBB, ensuring, for the first time, a sustained release of the embedded drug, and that these Np are able to reach all the brain areas here examined. The ability to enter the CNS appears to be linked to the sequence of the peptidic moiety present on their surface.
This paper references
10.1080/10611860600636135
Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats
Alessandra Ambruosi (2006)
Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines.
N. Eddy (1953)
10.1124/pr.57.2.4
The Blood-Brain Barrier/Neurovascular Unit in Health and Disease
B. Hawkins (2005)
10.1016/J.JCONREL.2005.07.013
Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier.
L. Costantino (2005)
10.1023/A:1018908421434
Biodegradable Nanoparticles Containing Doxorubicin-PLGA Conjugate for Sustained Release
H. Yoo (2004)
10.1016/J.JCONREL.2006.12.012
Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain.
J. Kreuter (2007)
10.1016/0040-4039(91)80548-K
Building blocks for glycopeptide synthesis: glycosylation of 3-mercaptopropionic acid and Fmoc amino acids with unprotected carboxyl groups
M. Elofsson (1991)
10.1023/A:1010931127745
Long-Circulating PEGylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery
P. Calvo (2004)
10.1016/0378-5173(89)90281-0
Nanocapsule formation by interfacial polymer deposition following solvent displacement
H. Fessi (1989)
10.1023/A:1015841715384
Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid) Microspheres
S. Cohen (2004)
10.1016/S0731-7085(99)00312-X
Determination of loperamide in rat plasma and bovine serum albumin by LC.
H. Chen (2000)
10.1016/0024-3205(96)00483-3
Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers.
M. Fontaine (1996)
10.1124/jpet.105.097139
Covalent Linkage of Apolipoprotein E to Albumin Nanoparticles Strongly Enhances Drug Transport into the Brain
K. Michaelis (2006)
10.1034/j.1600-0773.2000.pto870202.x
Role of cholecystokinin receptors in induction of antinociception in hot-plate test.
M. Rezayat (2000)
10.1080/10611860500411043
Body distribution of polysorbate‐80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats
Alessandra Ambruosi (2005)
10.1021/JS9604117
A theoretical model of erosion and macromolecular drug release from biodegrading microspheres.
R. Batycky (1997)
10.1021/CR040002S
Controlled ring-opening polymerization of lactide and glycolide.
O. Dechy-Cabaret (2004)
10.1016/J.BIOMATERIALS.2006.04.026
Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures.
L. Costantino (2006)
10.1023/A:1011988024295
BBB Transport and P-glycoprotein Functionality Using MDR1A (-/-) and Wild-Type Mice. Total Brain Versus Microdialysis Concentration Profiles of Rhodamine-123
E. C. D. de Lange (2004)
10.1016/S0939-6411(99)00073-9
Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system.
A. Friese (2000)
10.1023/A:1018947208597
Indirect Evidence that Drug Brain Targeting Using Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles Is Related to Toxicity
J. Olivier (2004)
10.1038/85045
Drug delivery via the blood–brain barrier
R. Edwards (2001)
10.1021/JM00001A021
Glycosylated peptide hormones: pharmacological properties and conformational studies of analogues of [1-desamino,8-D-arginine]vasopressin.
J. Kihlberg (1995)
10.1016/S0378-5173(02)00433-7
Minimization of initial burst in poly(vinyl alcohol) hydrogels by surface extraction and surface-preferential crosslinking.
X. Huang (2002)
10.3109/02652049609026036
Microencapsulation of ovalbumin in poly(lactide-co-glycolide) by an oil-in-oil (o/o) solvent evaporation method.
T. Uchida (1996)
10.1016/0168-3659(94)90026-4
The influence of biodegradable microcapsule formulations on the controlled release of a protein
H. Sah (1994)
10.1002/MED.20039
Glycosylated neuropeptides: A new vista for neuropsychopharmacology?
R. Polt (2005)
10.1016/J.JCHROMB.2004.10.037
Determination of Rhodamine 123 in cell lysate by HPLC with visible wavelength detection.
Tahira Iqbal (2005)
10.1016/J.IJPHARM.2005.03.031
Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain?
E. García-García (2005)
10.1016/J.POLYMDEGRADSTAB.2006.03.004
Preparation of poly(lactide-co-glycolide-co-caprolactone) nanoparticles and their degradation behaviour in aqueous solution
Hanwei Zhang (2006)
10.1016/J.BIOMATERIALS.2004.10.025
Conjugated poly(D,L-lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles.
G. Tosi (2005)
10.1016/S0006-8993(98)00571-X
Central analgesic actions of loperamide following transient permeation of the blood brain barrier with Cereport™ (RMP-7)
D. Emerich (1998)
10.1016/S0968-0896(97)00050-3
Modulation of nucleic acid structure by ligand binding: induction of a DNA.RNA.DNA hybrid triplex by DAPI intercalation.
Z. Xu (1997)
Long-circulating and target-specific nanoparticles: theory to practice.
S. Moghimi (2001)
10.1002/cncr.20073
Pegylated liposomal doxorubicin‐efficacy in patients with recurrent high‐grade glioma
P. Hau (2004)
10.1023/A:1012098005098
Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles
R. Alyautdin (2004)
10.3109/02652049209021219
Influence of the surface properties of low contact angle surfactants on the body distribution of 14C-poly(methyl methacrylate) nanoparticles.
S. Tröster (1992)
10.1073/PNAS.93.24.14164
Brain drug delivery of small molecules using immunoliposomes.
J. Huwyler (1996)
10.1358/DOF.2004.029.01.872585
Novel delivery systems for drug targeting to the brain
J. S. Reddy (2004)
10.1016/0006-8993(95)00023-J
Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles)
J. Kreuter (1995)
10.1023/A:1018983904537
Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles
A. Gulyaev (2004)
10.1016/j.addr.2012.09.015
Nanoparticulate systems for brain delivery of drugs.
J. Kreuter (2001)
10.1124/MI.3.2.90
Blood-brain barrier drug targeting: the future of brain drug development.
W. Pardridge (2003)
10.1081/DDC-120001481
Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier
P. Lockman (2002)
10.1016/S0168-3659(97)00061-8
Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood–brain barrier using surfactant-coated nanoparticles
J. Kreuter (1997)
10.2174/092986706777452461
Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue?
M. Ricci (2006)
10.1002/ijc.20048
Chemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticles
S. C. Steiniger (2004)
10.1016/S0168-3659(96)01475-7
Protein-loaded poly(dl-lactide-co-glycolide) microparticles for oral administration: formulation, structural and release characteristics
H. Rafati (1997)



This paper is referenced by
10.1016/j.jconrel.2010.03.008
Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution.
G. Tosi (2010)
10.1533/9781908818195.1
Nanoparticulate systems as drug carriers: the need
V. Patravale (2012)
10.2217/nnm.12.90
Nanomedicine: the future for advancing medicine and neuroscience.
G. Tosi (2012)
10.1016/j.ijpharm.2017.05.015
Novel Curcumin loaded nanoparticles engineered for Blood-Brain Barrier crossing and able to disrupt Abeta aggregates.
Ruozi Barbara (2017)
10.1016/B978-0-12-386986-9.00009-0
Neurotrophic factors and neurodegenerative diseases: a delivery issue.
B. Ruozi (2012)
10.1016/j.ejps.2012.04.013
Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
M. Fazil (2012)
10.1517/17425240902758188
Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases
Thomas M. Barchet (2009)
10.1016/j.biomaterials.2016.08.021
Graphene quantum dots conjugated neuroprotective peptide improve learning and memory capability.
S. Xiao (2016)
10.1002/mabi.201000005
Carboxymethylchitosan/poly(amidoamine) dendrimer nanoparticles in central nervous systems-regenerative medicine: effects on neuron/glial cell viability and internalization efficiency.
A. Salgado (2010)
10.1021/acs.molpharmaceut.5b00002
Liposomes Coloaded with Elacridar and Tariquidar To Modulate the P-Glycoprotein at the Blood-Brain Barrier.
Rita Nieto Montesinos (2015)
10.1016/j.jconrel.2015.06.002
PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier.
C. Fornaguera (2015)
10.1016/j.tibtech.2008.04.005
Multifunctional nanoparticles--properties and prospects for their use in human medicine.
Nuria Sanvicens (2008)
Development and characterization of artificial viruses for gene therapy
Joan Domingo i Espín (2013)
10.2147/IJN.S32701
Brain-targeting study of stearic acid–grafted chitosan micelle drug-delivery system
Yi-ting Xie (2012)
10.1517/17425247.5.2.155
Polymeric nanoparticles for the drug delivery to the central nervous system
G. Tosi (2008)
Recent Advances and Application of Nanotechnology in Drug Delivery Systems : A Review
Mittal (2017)
10.1007/978-3-319-41421-8_2
Nanoprecipitation Process: From Particle Preparation to In Vivo Applications
Karim Miladi (2016)
10.2147/IJN.S130908
Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis
P. Marcianes (2017)
10.22270/JDDT.V3I4.550
IN VIVO METHODS TO STUDY UPTAKE OF NANOPARTICLES INTO THE BRAIN
Harpreet Kaur (2013)
10.1016/j.ijpharm.2015.05.029
Nutlin-3 loaded nanocarriers: Preparation, characterization and in vitro antineoplastic effect against primary effusion lymphoma.
D. Belletti (2015)
10.1586/14737175.2015.1036743
Nano-ropinirole for the management of Parkinsonism: blood–brain pharmacokinetics and carrier localization
G. Mustafa (2015)
10.1007/978-1-4939-0363-4_12
A method for evaluating nanoparticle transport through the blood-brain barrier in vitro.
D. Guarnieri (2014)
10.1016/j.carbpol.2012.02.051
Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation.
S. Haque (2012)
10.1016/j.addr.2016.08.012
Building the design, translation and development principles of polymeric nanomedicines using the case of clinically advanced poly(lactide(glycolide))-poly(ethylene glycol) nanotechnology as a model: An industrial viewpoint.
H. R. Lakkireddy (2016)
10.1016/j.jconrel.2012.03.026
Therapeutics, imaging and toxicity of nanomaterials in the central nervous system.
António Nunes (2012)
Novel Polysaccharide Based Polymers and Nanoparticles for Controlled Drug Delivery and Biomedical Imaging
Alireza Shalviri (2012)
10.1039/C8TB02952K
Development of biodegradable polyesters based on a hydroxylated coumarin initiator towards fluorescent visible paclitaxel-loaded microspheres.
Yufei Bian (2019)
10.1016/j.biotechadv.2015.02.004
BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS.
H. Peluffo (2015)
10.1007/s00702-010-0497-1
NIR-labeled nanoparticles engineered for brain targeting: in vivo optical imaging application and fluorescent microscopy evidences
G. Tosi (2010)
10.1080/17425247.2020.1698544
Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier
G. Tosi (2019)
10.1088/2632-959x/ab9008
Peptide based drug delivery systems to the brain
Y. Islam (2020)
10.1007/978-3-662-43787-2
The Blood Brain Barrier (BBB)
G. Fricker (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar